The structural flaws accommodate a much higher quantity of encapsulated therapeutic agents.
Nanostructured Lipid Carrier (NLC) based Targeted Drug Delivery Solution
In the pursuit of groundbreaking therapies, the efficient and safe delivery of challenging drug molecules is paramount. Our Nanostructured Lipid Carriers (NLCs)-based Delivery Systems Solution helps you accelerate therapeutic development and enhance drug bioavailability through advanced lipid engineering and targeted modification techniques. This modern platform is engineered to overcome solubility and stability hurdles, transforming poorly performing drug candidates into highly effective nanomedicines.
Click Here to View more about our Services
Introduction of Nanostructured Lipid Carriers (NLCs)
Nanostructured Lipid Carriers (NLCs) represent the evolution of lipid nanocarriers, surpassing the limitations of first-generation Solid Lipid Nanoparticles (SLNs) which often suffered from low drug loading capacity and drug leakage due to the highly crystalline nature of their solid lipid core.
Fig.1 Structural matrix of SLN and NLC.1
Structure & Function: NLCs are colloidal carrier systems, typically ranging from 50 nm to 500 nm in diameter. The core of an NLC is a sophisticated mixture of solid lipids (like triglycerides or fatty acids) and a small percentage of liquid lipids (oils). This blending creates structural imperfections within the core matrix, resulting in a less organized, amorphous, or "disordered" state. This unique, non-crystalline arrangement serves three primary functions:
Increases Interior Space
Prevents Crystallization
It stabilizes the formulation, preventing the lipids from fully crystallizing over time, which minimizes drug expulsion.
Modulates Release
The semi-solid matrix dictates the diffusion rate of the encapsulated drug, enabling sustained release profiles.
The final structure of the SLN is highly dependent on factors like formulation components, drug solubility, and the production method. Three distinct internal structural models are reported for SLNs:
SLN Homogeneous Matrix Model (Type I)
In this structure, the drug is dissolved uniformly throughout the solid lipid matrix. Particles are typically produced via cold or hot homogenization for very lipophilic drugs. While offering stability, the highly ordered crystalline structure often limits drug loading capacity and can cause drug expulsion (leakage) during long-term storage.
SLN Drug-Enriched Shell Model (Type II)
This structure may be produced by the hot homogenization technique followed by cooling. The lipid molecules precipitate first, forming a solid core. The remaining melted lipid, now highly concentrated with the drug (until its solubility limit is reached), crystallizes to form an outer shell enriched with the drug. This model is not optimal for prolonged release but is valuable for increasing drug penetration in topical applications due to the occlusive effect of SLNs.
SLN Drug-Enriched Core Model (Type III)
This model forms when the drug concentration is near its solubility limit in the melted lipid, causing the drug to precipitate first and form a drug-enriched core. The shell is then composed of the solid lipid and a low drug concentration. This type is the opposite of Type II and is generally sought after for optimizing prolonged drug release profiles.
NLCs have demonstrated superior performance across numerous preclinical and clinical studies. Research highlights their successful application in delivering hydrophobic drugs, improving their oral bioavailability by enhancing intestinal lymphatic transport and mucosal permeability. Furthermore, their biocompatibility, biodegradability, and use of physiological lipids position them as an ideal and safe delivery platform for modern nanomedicine, supporting drug candidates that interact with complex biological systems and pathways.
Application in Modern Therapeutics
The structural advantages of Nanostructured Lipid Carriers translate directly into versatile applications across various pharmaceutical fields, enabling the realization of previously challenging therapeutic strategies.
Oncology & Targeted Therapy
NLCs are highly effective in cancer treatment due to their ability to exploit the Enhanced Permeability and Retention (EPR) effect in solid tumors (passive targeting). By functionalizing the NLC surface with tumor-specific ligands (e.g., folate, transferrin receptor ligands), we can achieve active targeting, concentrating high doses of chemotherapy or gene therapy agents specifically at the disease site, thereby maximizing anti-tumor efficacy and reducing systemic toxicity.
Topical & Transdermal Delivery
Due to their small size and lipid composition, NLCs can significantly enhance skin penetration and retention. They form an occlusive layer that promotes skin hydration and facilitates the deep deposition of active ingredients, making them superior carriers for anti-inflammatory, antioxidant, and cosmetic agents.
Ocular & Nasal Delivery
NLCs can improve the retention time and bioavailability of drugs in sensitive areas like the eye and nasal cavity. They help overcome natural barriers, ensuring sufficient therapeutic levels reach the target tissues, which is crucial for treating neurodegenerative disorders via nasal-to-brain pathways.
Oral Bioavailability Enhancement
For orally administered drugs with poor solubility (BCS Class II and IV), NLCs significantly increase bioavailability by solubilizing the drug and facilitating uptake, minimizing degradation in the gastrointestinal tract.
What We Can Offer
We recognize that many promising pharmaceutical compounds, particularly lipophilic small molecules and fragile nucleic acids, are limited by poor aqueous solubility, rapid degradation, and non-specific biodistribution. Creative Biolabs' NLC-based platform is specifically designed to address these critical limitations by offering a highly versatile, second-generation lipid carrier.
Our systems assist your project by providing:
Maximized Drug Loading
NLCs feature a unique, highly disordered core matrix, a blend of solid and liquid lipids. This structure prevents drug expulsion during storage, significantly increasing the total drug payload compared to earlier lipid-based systems like Solid Lipid Nanoparticles (SLNs).
Sustained & Controlled Release
The semi-solid nature of the NLC core allows for predictable, long-term drug release kinetics, minimizing dosing frequency and maintaining therapeutic concentrations over extended periods.
Enhanced Stability & Shelf-Life
Encapsulation within the robust, physiological lipid shell protects the payload from enzymatic and hydrolytic degradation, ensuring drug integrity until it reaches the site of action.
Targeting Versatility
We offer expertise in surface functionalization, allowing NLCs to be decorated with various targeting ligands—peptides, antibodies, or aptamers—to achieve active, site-specific delivery to tissues or cells of interest, such as tumor microenvironments or across the blood-brain barrier.
By choosing our NLC solutions, you gain a system optimized for regulatory compliance and scalability, dramatically improving the therapeutic index of your candidate.
FAQs
Why should I choose Nanostructured Lipid Carriers (NLCs) over traditional liposomes for my therapeutic agent?
While both are excellent nanocarriers, NLCs offer a unique advantage in their core structure. Traditional liposomes have an aqueous interior that is ideal for hydrophilic drugs, but NLCs—with their semi-solid lipid core—are superior for accommodating high concentrations of hydrophobic, poorly soluble drugs. The disordered structure of the NLC core also provides better physical stability and significantly minimizes the risk of drug leakage, which is a common limitation in liposomal formulations during long-term storage.
How can these nanocarriers help improve the bioavailability of my poorly water-soluble drug candidate?
The nanocarriers improve bioavailability through several synergistic mechanisms. Their small, uniform size increases the surface area for absorption in the GI tract. More importantly, by encapsulating the drug within a lipid matrix, they facilitate absorption via lymphatic pathways, bypassing the extensive first-pass metabolism in the liver. This protection and increased absorption surface area dramatically enhance the systemic exposure of the therapeutic agent.
What is the typical particle size range for these systems, and how does size affect biological performance?
The optimal size range is typically between 50 nm and 200 nm. Size is a critical factor for two reasons: particles smaller than 200 nm are generally required to exploit the Enhanced Permeability and Retention (EPR) effect for passive tumor targeting. Furthermore, smaller particles are less readily cleared by the mononuclear phagocyte system (MPS), allowing for extended circulation time and greater accumulation at the target site.
What are the main formulation precautions I need to consider when designing an NLC system?
The most critical factors are the ratio and type of solid lipid to liquid lipid, and the selection of the emulsifier (surfactant). The specific ratio determines the core's internal disorder, which directly impacts drug loading and stability. Furthermore, using physiologically compatible lipids and biocompatible surfactants is essential to ensure low toxicity and regulatory compliance for in vivo use. Careful optimization of these components is key to a successful, stable formulation.
Can these lipid carriers be modified to target the central nervous system (CNS)?
Yes, the lipophilic nature of these carriers provides a foundational advantage in crossing lipid-based biological barriers, including the blood-brain barrier (BBB). For enhanced and active targeting to the CNS, the surface can be functionalized with specific ligands, such as peptides or transferrin receptor antibodies, which utilize receptor-mediated transport mechanisms to actively ferry the nanocarriers across the BBB, significantly improving therapeutic delivery to the brain.
Creative Biolabs' Nanostructured Lipid Carriers (NLCs)-based Delivery Systems Solution offers a strategic, high-performance path for developing modern nanomedicines. Our proven platform, backed by two decades of lipid engineering expertise, delivers superior drug loading, enhanced stability, and controlled release for your most challenging compounds. We are your dedicated partner in overcoming delivery hurdles and accelerating your therapeutic pipeline towards the clinic.
Reference
- Viegas, Cláudia et al. "Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review." Pharmaceutics vol. 15,6 1593. 25 May. 2023, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/pharmaceutics15061593.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
